Figitumumab
From Self-sufficiency
Revision as of 10:08, 9 August 2010 by RjwilmsiBot (Talk) (→Clinical trials: CiteCompletion, authors: 1, using AWB (6973))
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Template:Infobox drug/mab source |
| Target | IGF-1 receptor |
| Identifiers | |
| CAS Number | 943453-46-1 |
| ATC code | none |
| Chemical data | |
| Formula | C6462H9948N1736O2020S54 |
| Molar mass | 146.0 kDa[[Script error: No such module "String".]] |
Figitumumab (previously CP-751871) is a monoclonal antibody[1] targeting the insulin-like growth factor-1 receptor being investigated for the treatment of various types of cancer, for example adrenocortical carcinoma[2] and non-small cell lung cancer (NSCLC)[3].
This drug is being developed by Pfizer.
Anti-cancer mechanism
See Insulin-like growth factor 1 receptor role in cancer.
Clinical trials
The first phase III trial (for NSCLC) was suspended in December 2009 due to excess deaths[4] but others continue[5][6].
It will be included in the forthcoming I-SPY2 breast cancer trial.[7]
References
- ↑ Statement On A Nonproprietary Name Adopted By The Usan Council - Figitumumab, American Medical Association.
- ↑ Haluska, P; Worden, F; Olmos, D; Yin, D; Schteingart, D; Batzel, GN; Paccagnella, ML; De Bono, JS; Gualberto, A (2009). "Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma". Cancer chemotherapy and pharmacology. doi:10.1007/s00280-009-1083-9. PMID 19649631.
- ↑ Gualberto, A; Karp, DD (2009). "Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer". Clinical lung cancer. 10 (4): 273–80. doi:10.3816/CLC.2009.n.038. PMID 19632947.
- ↑ Krauskopf, Lewis (29 December 2009). "Pfizer ends late-stage lung-cancer study". Reuters.
- ↑ ClinicalTrials.gov NCT00976508 Figitumumab Combined With Pegvisomant For Advanced Solid Tumors
- ↑ ClinicalTrials.gov NCT00635245 CP-751871 in Treating Women With Early-Stage Breast Cancer That Can Be Removed by Surgery
- ↑ "Breast cancer study aims to speed drugs, cooperation". Reuters. March 2010.
| 40x30px | This monoclonal antibody-related article is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Drugs that are a monoclonal antibody
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- 2Fix
- Cancer treatments
- Pfizer
- Pages with broken file links
- Monoclonal antibody stubs
